死亡风险降低50%！EGFR 20号外显子插入突变肺癌，即将迎来新的联合疗法 | 2026WCLC

肺癌患者拿到基因检测报告，看到“EGFR突变”，往往会想到靶向治疗。但EGFR突变并不是一种单一类型，不同突变类型，对靶向药的敏感性也可能不同。 比如，EGFR ...

Cancer treatment moves to earlier stages: 6 clinical trials including 3 FDA approvals

From October 3 to October 9, we covered 6 topics in the oncology field (there were no topics in the neurology field). Of these, 3 were FDA approvals, and 5 out of the 6 involved moves to expand drugs ...

It was supposed to be '9 minutes 37 seconds', but actual measurement showed 9 minutes 29 seconds—closing in on the mystery of the 8 seconds left on a 50-year-ol…

For the generation that listens to music via current subscriptions and streaming, the idea of changing the rotation speed to ...

出海临床试验遇挫，艾力斯伏美替尼海外III期临床未达终点，美股合作方股价单日暴跌近50%

红星资本局10月7日消息，10月6日，艾力斯（688578.SH）海外合作伙伴ArriVent BioPharma（AVBP，下称ArriVent）宣布，伏美替尼（firmonertinib）用于一线治疗EGFR外显子20插入突变非小细胞肺癌的全球III期FURVENT研究，未达到主要终点。当日，ArriVent股价一度暴跌近60%，收盘跌幅46.98%。 红星资本局注意到，伏美替尼由艾力斯原研、 ...
메디칼업저버

EGFR TKI 실패 후 CNS 전이 폐암, 렉라자 기반 치료 두개강내 ORR 50%

KCSG LU20-15 연구는 1, 2세대 EGFR TKI 치료 실패 후 측정 가능한 뇌전이가 있는 환자에게 렉라자를 투여했다. 총 40명 중 조기 중단으로 평가 불가능했던 2명을 제외한 38명이 이번 통합분석에 포함됐다.
MedPage Today

Chemo-Free Regimen May Be Effective Option for EGFR-Mutant Lung Cancer

A three-drug combination may be effective for patients with EGFR -mutant advanced non-small cell lung cancer (NSCLC) who ...

HER2-Positive Breast Cancer - Global Drug Pipeline Insight, 2026 | 50+ Companies Advance 55+ Therapies as ADCs and Next-Generation HER2 Inhibitors Drive Deal Opportunities

Global, stage-by-stage insights into HER2-positive breast cancer therapies, clinical activity, unmet needs, partnerships and inactive assets.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "HER2-Positive ...
MyHorryNews.com

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

These results were presented during the Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) (Late-breaking Abstract ...
x

Stephen V Liu, MD on X: "Dr. @danieltanmd presents REZILIENT 3 at #WCLC26: 1L zipalertinib + chemo vs chemo in EGFR exon 20 insertion NSCLC. Superior PFS 14.5 vs 8.5m (HR 0.50 ...

Thoracic Oncologist, Chief of Heme/Onc @Georgetown @MedStarGUH, Head of Developmental Therapeutics @LombardiCancer, #DCLung26 #TexasLung27 #HereWeGo #LetsGoBucs ...